American Journal of Hematology · 2002 · 17 citations · 11 references
MedicineGeneticsHematologyHematologic OncologyHematopathologyMedical GeneticsBone Marrow PathologyGenetic DisordersHematologic MalignanciesHematopoietic NeoplasmsMyeloproliferative NeoplasmsBone Marrow - Derived CellsMissense MutationsMyeloid NeoplasmsP53 InactivationP53 MutationTumor Suppressor Gene LossTumor Suppressor Gene MutationsTumor Suppressor P53
Alterations of the N-ras oncogene and p53 tumor suppressor gene have been demonstrated to play an important role in pathogenesis of hematological malignancies. We simultaneously investigated genetic lesions of both genes in bone marrow cells from 64 Japanese patients with myeloproliferative disorders (MPD), including polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (MF), by direct sequencing analysis. No mutations of the N-ras gene were detected in any cases. Two patients, one with chronic neutrophilic leukemia derived from PV and one with acute mylogenous leukemia derived from ET, exhibited three mutations of the p53 gene. Among them, two were missense mutations in exon 5 or 7 and one was a deletion in exon 5. All samples in chronic phase or from MF were devoid of mutations in both genes. These data suggested that disruptions of both genes are extremely rare in MPD in chronic phase and that loss of functions in the p53 gene could be involved in progression of MPD such as PV and ET.
11
Diagnosis and classification of the polycythemias.
Nathaniel I. Berlin · PubMed · 1975 · 559 citations
Medicine, Hematology, Pathology +5
Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group.
Seamus Murphy, Harry Iland, David S. H. Rosenthal et al. · PubMed · 1986 · 485 citations
Johannes W.G. Janssen, Ada C. M. Steenvoorden, J Lyons et al. · Proceedings of the National Academy of Sciences · 1987 · 228 citations · Full text
Medicine, Genetics, Hematology +17